Because reducing Aβ level is a therapeutic strategy for AD treatment, our results as well as others suggest that ubiquilin-1 is an AD therapeutic target and that overexpressing UBQLN1 may be considered as a potential therapeutic strategy. Here, UBQLN1 is linked to Alzheimer disease.